# A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07327229** · PHASE1,PHASE2 · RECRUITING · sponsor: **Antengene Biologics Limited** · enrollment: 132 (estimated)

## Conditions studied

- Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** ATG-022
- **DRUG:** pembrolizumab/KEYTRUDA®
- **DRUG:** CAPOX

## Key facts

- **NCT ID:** NCT07327229
- **Lead sponsor:** Antengene Biologics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-27
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327229, "A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07327229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*